LDOS — Leidos Holdings, Inc.

The mood turned positive after Q2 2026 revenue of $4.56B (+7.2% YoY), adjusted EPS of $3.26 versus $2.91 consensus, and a raise to full-year EPS guidance of $12.20–$12.50. Fresh contract wins, a new 20M-share buyback, and a $0.43 quarterly dividend add to the constructive tone. As of 2026-08-27, the stock remains below the analyst consensus target of $155.29, and RSI of 61 shows momentum building without being overbought.

Revenue growth has been steady to modestly accelerating: from roughly $3.92B in the Sep-2023 quarter to $4.56B in Jul-2026, with recent YoY prints of +2.9%, +6.7%, -3.6% (a quarterly timing dip), +3.7%, and +7.2%. The Sep-2023 quarter included a large one-off operating loss of -$336M and EPS of -$2.91, so the underlying 3-year trend is profitable and stable. Reported GAAP operating margin was 11.1% in Jul-2026 versus 13.4% a year earlier and GAAP EPS fell from $3.01 to $2.81, but adjusted earnings beat and guidance rose, indicating the reported dip is more charge-related than operational deterioration. Free cash flow is the standout: Q2 2026 FCF was $761M versus $457M a year ago.

Cheap on both absolute and relative bases. Trailing P/E is 12.94x, forward P/E on next-fiscal-year consensus EPS of $12.385 is about 11.3x, versus Leidos' own 5-year average P/E of 28.88x. Price-to-sales is 1.00x versus the 5-year average of 1.09x. The trailing PEG of 10.63 is distorted by a slow trailing earnings base; with forward EPS growth near 12.6%, the forward PEG is roughly 0.9x. At a 1.48% dividend yield and a 1.0x sales multiple, the stock is not being priced like a quality compounder.

At $139.86, the market is pricing around 11x this year's raised EPS guidance. That leaves little room for disappointment, but it also means the stock is not pricing in the contract-win momentum, buyback, or margin upside. If Leidos hits $12.20–$12.50 of EPS and the multiple merely normalizes to 13x, the stock is worth roughly $159–$163. This looks like an underpriced-earnings setup after a sharp derating from $205, not a stock where price has run ahead of fundamentals.

As of 2026-08-27, RSI stood at 61.03, positive but not overbought. Price was 2.22% above the 20-day SMA and 17.32% above the 50-day SMA, yet still 9.68% below the 200-day SMA, which sits near $155. The short-term trend has turned up while the longer-term trend remains down. The $150–$156 zone is key resistance; a decisive move above the 200-day would confirm a broader trend reversal, while current levels are more of an early-recovery entry for patient investors.

• Sustained geopolitical tension and elevated U.S. defense, homeland security, and intelligence budgets are a multi-year tailwind for Leidos' core mission-IT and cyber franchises.
• Government budget execution risk remains: continuing resolutions, debt-ceiling fights, or future austerity could delay awards and backlog conversion.
• With $6.0B of long-term debt, higher-for-longer interest rates raise refinancing and interest costs, though predictable government cash flows provide relative insulation.
• AI-infused cybersecurity and digital modernization procurement trends are shifting contract mix toward higher-margin work.
• IT-services labor market wage inflation remains a margin watch-item, though Leidos' scale and cleared workforce provide pricing power.

• Q3 2026 earnings, tentatively late October to early November 2026; another beat or guidance raise would reinforce the re-rating story.
• Execution and scaling of the $301M Department of War cyber operations contract and the $56M Naval Health Research Center award.
• Capital returns: the 20M-share buyback authorization and $0.43 quarterly dividend support per-share value.
• Analyst target revisions; BNP Paribas Exane recently moved to $175, and further post-earnings upgrades are possible.
• A full-year defense appropriations bill replacing continuing resolutions could improve award cadence.

• U.S. defense/IT budget cuts, extended continuing resolutions, or a procurement slowdown would pressure revenue growth and backlog.
• Balance-sheet leverage: long-term debt of $6.0B versus stockholders' equity of $5.3B leaves limited headroom if rates stay high.
• The GAAP-to-adjusted EPS gap is notable: Jul-2026 GAAP EPS was $2.81 versus $3.26 adjusted, so reported earnings can be dragged by charges and amortization.
• High customer concentration in U.S. government agencies makes recompetes and protest outcomes highly impactful.
• The valuation multiple may stay low if investors continue to discount government-services businesses despite improving earnings.

Leidos is a well-managed, cash-generative government technology contractor trading at roughly 11.3x forward earnings with accelerating revenue, record free cash flow, and raised guidance. The risk/reward skews positive, but the still-bearish long-term technical picture and elevated leverage argue for building the position patiently rather than chasing a breakout.

Calculated by applying a conservative 13.5x multiple to next-fiscal-year consensus EPS of $12.385, yielding roughly $167, and cross-checking against the historical average P/S of 1.09x on 2026E revenue per share of about $145.65, yielding roughly $159; blending those gives $163.0. This assumes a modest re-rating from the current 11.3x forward multiple, not a return to the 28.9x five-year trailing average.